The Multiple Myeloma (MM) market is currently dominated by Velcade and Revlimid, and the market is set to undergo substantial growth between 2013 and 2023. The main drivers of growth will be the launch of monoclonal antibodies (mAbs) Empliciti and daratumumab, which will not only provide a new treatment option for MM patients, but will also lengthen the time between relapses, meaning that the duration of Revlimid and/or Velcade treatments will also be longer. Furthermore, the relatively mild safety profile of these mAbs and the significant efficacies demonstrated by these agents will mean that more MM patients will ultimately receive drug treatment. Label extensions of these mAbs, as well as of second-generation proteasome inhibitors ixazomib and Kyprolis, will further increase treatment options for these patients. The biggest constrainers of the MM market are the increasing cost-consciousness of healthcare providers, as the launch and subsequent label extensions of these pipeline agents will lead to a significant expense, which may impact uptake of these drugs. The patent expiries of Revlimid and Velcade will somewhat alleviate healthcare spending on multiple myeloma patients, which may assist in the uptake of mAbs and second-generation PIs in the multiple myeloma market.
The 5EU market is forecast to show a larger increase in size. This is due to the launch of premium priced Kyprolis, Empliciti, and daratumumab, as well as the later launch of Revlimid and Velcade generics, compared to the US.
*This is an on-demand report and will be delivered within 24 hrs. (excluding weekends) of the purchase.
– Overview of Multiple Myeloma including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
– Detailed information on the key drugs in 5EU including product description, safety and efficacy profiles as well as a SWOT analysis.
– Sales forecast for the top drugs in 5EU from 2014-2024.
– Analysis of the impact of key events as well the drivers and restraints affecting 5EU Multiple Myeloma market.
Reasons to buy
– Understand and capitalize by identifying products that are most likely to ensure a robust return
– Stay ahead of the competition by understanding the changing competitive landscape for Multiple Myeloma.
– Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
– Make more informed business decisions from insightful and in-depth analysis of drug performance
– Obtain sales forecast for drugs from 2014-2024 in 5EU.
Table of Content:
8 Market Outlook 115
8.1 5EU 115
8.1.1 Forecast 115
8.1.2 Key Events 119
8.1.3 Drivers – 5EU 119
8.1.4 Barriers – 5EU 121
9 Appendix 124
9.1 Bibliography 124
9.2 Abbreviations 146
9.3 Methodology 150
9.4 Forecasting Methodology 150
9.4.1 Diagnosed Multiple Myeloma Patients 150
9.4.2 Percent of Drug-Treated Patients 151
9.4.3 Drugs Included in Each Therapeutic Class 151
9.4.4 Launch and Patent Expiry Dates 152
9.4.5 General Pricing Assumptions 153
9.4.6 Individual Drug Assumptions 154
9.4.7 Pricing of Pipeline Agents 161
9.4.8 Generic Erosion 168
9.5 Primary Research – KOLs Interviewed for this Report 169
9.6 Primary Research – High-Prescriber Survey 171
9.7 About the Authors 172
9.7.1 Analyst 172
9.7.2 Therapy Director 172
9.7.3 Epidemiologist 172
9.7.4 Global Head of Healthcare 173 Continued……
1.1 List of Tables
Table 1: Definition of the Classes of Myeloma 15
Table 2: Staging Systems for Multiple Myeloma 17
Table 3: IMWG Uniform Response Criteria for Multiple Myeloma: Response 18
Table 4: IMWG Uniform Response Criteria for Multiple Myeloma: Progression 18
Table 5: Symptoms of Multiple Myeloma 19
Table 6: Median Survival for Each Stage at Diagnosis of Multiple Myeloma 20
Table 7: Potential Diagnostic Markers that Predict Two-Year Disease Progression 21
Table 8: Summary of Prevalence and Clinical Outcomes of Translocations in Multiple Myeloma 21
Table 9: Treatment Guidelines for Multiple Myeloma 25
Table 10: Definition of the Classes of Myeloma 26
Table 11: Most Prescribed Drugs for Multiple Myeloma by Class in the Global Markets, 2014 31
Table 12: Most-Prescribed Drugs for Multiple Myeloma by Segment in the Global Markets, 2013 32
Table 13: Country Profile – France 34
Table 14: Country Profile – Germany 37
Table 15: Country Profile – Italy 39
Table 31: Country Profile – Spain 42
Table 17: Country Profile – UK 45
Table 18: Product Profile – Velcade 48
Table 19: Results from the Pivotal Phase III APEX Trial for Velcade 50
Table 20: Results from the Pivotal Phase III VISTA Trial for Velcade 51
Table 21 Results from the Subcutaneous versus Intravenous Velcade Phase III trial 51
For more information or any query mail at email@example.com
Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.
WISE GUY RESEARCH CONSULTANTS PVT LTD
75 Arlington Street, Suite 500,
Boston, Massaachusetts – 02116
United States of America
+1 646 845 9349 / +44 208 133 9349